Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 17
2003 16
2004 17
2005 8
2006 18
2007 17
2008 16
2009 16
2010 15
2011 23
2012 25
2013 14
2014 11
2015 21
2016 20
2017 12
2018 20
2019 12
2020 8
2021 13
2022 11
2023 8
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Results by year

Filters applied: . Clear all
Page 1
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R, Mirtti T, Kilpeläinen TP, Tolonen T, Räisänen-Sokolowski A, Nordling S, Hannus J, Laurila M, Taari K, Tammela TLJ, Autio R, Natunen K, Auvinen A, Rannikko A. Hietikko R, et al. Among authors: tammela tlj. World J Urol. 2024 Apr 6;42(1):217. doi: 10.1007/s00345-024-04898-2. World J Urol. 2024. PMID: 38581590 Free PMC article.
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A, Tammela TLJ, Mirtti T, Lilja H, Tolonen T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Natunen K, Nevalainen J, Raitanen J, Ronkainen J, van der Kwast T, Riikonen J, Pétas A, Matikainen M, Taari K, Kilpeläinen T, Rannikko AS; ProScreen Trial Investigators. Auvinen A, et al. Among authors: tammela tlj. JAMA. 2024 Apr 6:e243841. doi: 10.1001/jama.2024.3841. Online ahead of print. JAMA. 2024. PMID: 38581254
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Shore ND, et al. Among authors: tammela tlj. Oncologist. 2024 Feb 23:oyae019. doi: 10.1093/oncolo/oyae019. Online ahead of print. Oncologist. 2024. PMID: 38394384 Free article.
Do LUTS Predict Mortality? An Analysis Using Random Forest Algorithms.
Åkerla J, Nevalainen J, Pesonen JS, Pöyhönen A, Koskimäki J, Häkkinen J, Tammela TLJ, Auvinen A. Åkerla J, et al. Among authors: tammela tlj. Clin Interv Aging. 2024 Feb 12;19:237-245. doi: 10.2147/CIA.S432368. eCollection 2024. Clin Interv Aging. 2024. PMID: 38371602 Free PMC article.
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.
Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X; Biobank Japan Project; Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M… See abstract for full author list ➔ Wang A, et al. Among authors: tammela tlj. Nat Genet. 2023 Dec;55(12):2065-2074. doi: 10.1038/s41588-023-01534-4. Epub 2023 Nov 9. Nat Genet. 2023. PMID: 37945903 Free PMC article.
Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases.
Sattari M, Kohvakka A, Moradi E, Rauhala H, Urhonen H, Isaacs WB, Nykter M, Murtola TJ, Tammela TLJ, Latonen L, Bova GS, Kesseli J, Visakorpi T. Sattari M, et al. Among authors: tammela tlj. Endocr Relat Cancer. 2023 Jun 26;30(8):e220247. doi: 10.1530/ERC-22-0247. Print 2023 Aug 1. Endocr Relat Cancer. 2023. PMID: 37140987 Free PMC article.
Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
Remmers S, Bangma CH, Godtman RA, Carlsson SV, Auvinen A, Tammela TLJ, Denis LJ, Nelen V, Villers A, Rebillard X, Kwiatkowski M, Recker F, Wyler S, Zappa M, Puliti D, Gorini G, Paez A, Lujan M, Nieboer D, Schröder FH, Roobol MJ. Remmers S, et al. Among authors: tammela tlj. Eur Urol. 2023 Nov;84(5):503-509. doi: 10.1016/j.eururo.2023.03.031. Epub 2023 Apr 21. Eur Urol. 2023. PMID: 37088597 Free PMC article. Clinical Trial.
297 results